Outset Medical (OM) Projected to Post Quarterly Earnings on Thursday

Outset Medical (NASDAQ:OM) will likely be issuing its Q1 2026 results after the market closes on Thursday, May 7th. Analysts expect the company to announce earnings of ($0.79) per share and revenue of $28.90 million for the quarter. Investors may visit the the company’s upcoming Q1 2026 earning results page for the latest details on the call scheduled for Thursday, May 7, 2026 at 4:30 PM ET.

Outset Medical Trading Down 0.7%

OM opened at $4.33 on Tuesday. Outset Medical has a 52 week low of $3.00 and a 52 week high of $21.98. The business has a fifty day simple moving average of $3.82 and a 200-day simple moving average of $5.44. The firm has a market cap of $80.23 million, a P/E ratio of -0.64 and a beta of 1.92. The company has a quick ratio of 5.40, a current ratio of 6.67 and a debt-to-equity ratio of 0.76.

Wall Street Analyst Weigh In

Several research analysts have recently commented on OM shares. Weiss Ratings restated a “sell (e+)” rating on shares of Outset Medical in a research report on Friday, March 27th. BTIG Research dropped their target price on Outset Medical from $17.00 to $15.00 and set a “buy” rating for the company in a research report on Thursday, February 12th. Wall Street Zen cut shares of Outset Medical from a “hold” rating to a “sell” rating in a research report on Saturday, April 11th. Finally, Stifel Nicolaus lowered their price objective on shares of Outset Medical from $14.00 to $8.00 and set a “buy” rating for the company in a research note on Wednesday, January 7th. One equities research analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, Outset Medical currently has a consensus rating of “Moderate Buy” and an average price target of $10.00.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. Los Angeles Capital Management LLC purchased a new stake in Outset Medical during the 4th quarter worth about $29,000. Legal & General Group Plc purchased a new position in shares of Outset Medical in the 2nd quarter valued at about $34,000. BNP Paribas Financial Markets grew its position in shares of Outset Medical by 7,013.8% during the second quarter. BNP Paribas Financial Markets now owns 2,063 shares of the company’s stock worth $40,000 after buying an additional 2,034 shares in the last quarter. Hsbc Holdings PLC acquired a new position in shares of Outset Medical during the fourth quarter worth about $46,000. Finally, HRT Financial LP purchased a new stake in shares of Outset Medical during the fourth quarter worth approximately $58,000.

About Outset Medical

Outset Medical is a medical technology company specializing in innovations for renal care. The company’s flagship offering, the Tablo Hemodialysis System, is designed to streamline and simplify dialysis treatment across acute and outpatient settings. By integrating water purification, dialysate production, and treatment monitoring into a single device, Tablo aims to reduce the complexity and logistical burden traditionally associated with hemodialysis therapy.

Tablo’s modular design allows for rapid setup and flexible deployment in hospitals, clinics, long?term care facilities and emergency response scenarios.